Latest News on HOLX

Financial News Based On Company


Advertisement
Advertisement

Electroceutical Devices Market Size, Share & Forecast 2036

https://www.factmr.com/report/electroceutical-devices-market
The electroceutical devices market is projected to grow from USD 25.1 billion in 2026 to USD 49.2 billion by 2036, at a CAGR of 7.0%. This growth is driven by increasing adoption of advanced neuromodulation, expansion of closed-loop and personalized neuromodulation, and strategic portfolio consolidation among key players. Implantable devices, cardiovascular applications, and hospitals are expected to maintain their leading positions in the market segments.

CEMENTOS PACASMAYO SAA Amended Tender Offer Recommendation

https://www.stocktitan.net/sec-filings/CPAC/sc-14d9-a-cementos-pacasmayo-saa-amended-tender-offer-recommendation-96851030b191.html
Cementos Pacasmayo S.A.A. (CPAC) has filed an Amendment No. 1 to its Schedule 14D-9, amending and supplementing a previously filed solicitation/recommendation statement regarding a tender offer by Inversiones ASPI S.A., a subsidiary of Holcim Ltd. The amendment clarifies that specific directors and executive officers intend to tender their Common Shares and/or ADSs in the offer. The tender offer is for outstanding Common Shares and American Depositary Shares (ADS) at S/ 8.93 per Common Share and S/ 44.65 per ADS.

Labcorp Holdings (LH) Following Earnings And Higher Guidance Is It Fully Valued

https://simplywall.st/stocks/us/healthcare/nyse-lh/labcorp-holdings/news/labcorp-holdings-lh-following-earnings-and-higher-guidance-i
Labcorp Holdings (LH) is under scrutiny after reporting strong Q3 earnings, upgraded full-year revenue guidance, and new collaborations, leading to a 43.6% year-to-date stock surge. While one valuation model suggests the stock is slightly overvalued at $361.39 against a fair value of $354.50, another discounted cash flow (DCF) model indicates it might be undervalued at $417.79. The differing valuations highlight the complexity in assessing LH's current price and future upside, making it a "judgment call" for investors.

West Pharmaceutical Services earnings: what to look for from WST

https://stockstory.org/us/stocks/nyse/wst/news/earnings/west-pharmaceutical-services-earnings-what-to-look-for-from-wst-3
West Pharmaceutical Services (NYSE:WST) is set to announce its earnings results this Thursday morning. The company previously exceeded revenue and EPS expectations, and analysts anticipate a 2.8% year-on-year revenue growth this quarter. Investor sentiment in the drug development inputs & services segment has been positive, with West Pharmaceutical Services's stock up 5.8% over the last month.

Thinking Out of the ‘Box’: NGS Platform Makers Eye Data Biz Amidst AI Biology Gold Rush

https://www.genomeweb.com/technology/sequencing/gnw-ngs-platform-makers-data-business-20261028/
Next-generation sequencing (NGS) platform manufacturers are reportedly looking beyond their traditional hardware business to capitalize on the growing demand for data in the artificial intelligence (AI) biology sector. This strategic shift aims to leverage the extensive genomic data generated by their platforms. The move signifies an evolving landscape in the genomics industry, where data is becoming as valuable as the sequencing technology itself.
Advertisement

Cementos Pacasmayo S.A.A. Q3 Earnings Call Highlights

https://www.tradingview.com/news/marketbeat:04888452f094b:0-cementos-pacasmayo-s-a-a-q3-earnings-call-highlights/
Cementos Pacasmayo S.A.A. (CPAC) reported strong third-quarter results with increased revenue, earnings, and margins, driven by higher cement demand, strategic pricing, and cost efficiencies. The company's CEO, Humberto Nadal, anticipates approximately 4% volume growth in 2027, contingent on El Niño's impact. Key financial improvements included a 45.1% rise in consolidated EBITDA and a 69.8% increase in net income.

Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP

https://uk.finance.yahoo.com/news/davion-healthcare-announces-us-25-113000696.html
Davion Healthcare Plc has acquired the intellectual property for two medical technologies, WoundSkan and Spektra Lateral Flow Test, from Humaskan Ltd for US$25 million. This acquisition, Davion's first since its Nasdaq listing, includes a battery-free smart wound dressing and a rapid multi-marker screening test, enhancing Davion's focus on health monitoring outside traditional clinical settings. The deal aligns with Davion's strategy of combining proprietary technology commercialization with strategic acquisitions to build an international healthcare business.

Bone Densitometer Devices Market Size, Forecast, Demand, Opportunities, 2034

https://straitsresearch.com/report/bone-densitometer-devices-market
The global bone densitometer devices market was valued at USD 262.60 million in 2025 and is projected to reach USD 373.76 million by 2034, growing at a CAGR of 4.00%. North America held the largest market share in 2025, while Asia Pacific is expected to be the fastest-growing region. The market growth is driven by the rising prevalence of osteoporosis, the need for early diagnosis, and the integration of advanced technologies like Trabecular Bone Score (TBS) into DXA workflows.

Medicare Begins Reimbursing Lucid Diagnostics’ EsoGuard Test

https://clpmag.com/lab-management/company-news/medicare-reimburses-lucid-esoguard-test-1938/
Lucid Diagnostics has started receiving Medicare reimbursement for its EsoGuard Esophageal DNA Test at $1,938 per test, allowing fully reimbursed access for Medicare beneficiaries nationwide. This milestone is crucial for the company's mission to prevent esophageal cancer through precancer testing and will aid in securing coverage from commercial payors. To support commercial expansion, Lucid also completed a $15 million private placement of convertible preferred stock.

QT Imaging Bolsters U.S. Commercial Strategy by Adding to its Salesforce

https://www.mpo-mag.com/breaking-news/qt-imaging-bolsters-u-s-commercial-strategy-by-adding-to-its-salesforce/
QT Imaging Holdings Inc. has enhanced its direct U.S. commercial strategy by appointing Jason Dyer and Dave Reinhart as regional sales VPs to lead sales in the East and West. These new hires, veterans in the breast imaging industry, aim to transition the company from a distributor-led model to an integrated commercial model. This strategic shift is intended to improve gross margins, strengthen customer engagement, and expand market development for its Breast Acoustic CT Scanner.
Advertisement

Cryoport stock faces estimated November 3 earnings report

https://www.ad-hoc-news.de/boerse/news/nebenwerte/cryoport-stock-faces-estimated-november-3-earnings-report/70349852
Cryoport (CYRX) is scheduled to release its next earnings report on November 3, 2026, after market close, with analysts estimating a consensus earnings per share of minus USD 0.19 and revenue of USD 48.69 million for the third quarter of 2026. The company's second-quarter revenue reached USD 48.97 million, and its stock closed at USD 16.84 on October 16, 2026, down 1.35 percent, with a market capitalization of USD 852.9 million. Cryoport, which provides temperature-controlled logistics for life sciences, has seen its stock rise 75.40 percent year-to-date.

Corbus Pharmaceuticals stock costs EUR 3.86 with volume 36.43 percent above average

https://www.ad-hoc-news.de/boerse/news/nebenwerte/corbus-pharmaceuticals-stock-costs-eur-3-86-with-volume-36-43-percent-above-average/70333388
Corbus Pharmaceuticals (CRBP) stock was trading at EUR 3.86 on October 15, 2026, with a trading volume of 1,089,233 shares, which is 36.43% above its average. The company, focused on oncology and obesity treatments, reported cash and investments of USD 118.0 million as of June 30, 2026, and an estimated earnings date of November 16, 2026. The stock's market capitalization is USD 83.7 million with a negative P/E ratio.

Raymond James keeps USD 95.00 target for RadNet stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/raymond-james-keeps-usd-95-00-target-for-radnet-stock/70332324
Raymond James has reiterated its "Strong Buy" rating and a USD 95.00 price target for RadNet (RDNT) stock. RadNet's stock closed at EUR 61.91 on October 15, 2026, and the company is expected to report its third-quarter results on November 9, 2026, with anticipated revenues of USD 639.97 million and EPS of USD 0.2214. The target price represents a significant upside from its current Nasdaq quote.

Freedom Capital sets USD 36.00 target for HealthStream stock

https://www.ad-hoc-news.de/boerse/news/nebenwerte/freedom-capital-sets-usd-36-00-target-for-healthstream-stock/70331813
Freedom Capital has initiated coverage on HealthStream (HSTM) with a Hold rating and a USD 36.00 price target. This target is 7.05 percent higher than the Nasdaq price of USD 33.63. The article highlights HealthStream's strong second-quarter revenue growth of 12.5 percent to USD 83.73 million and its market capitalization of USD 1.0 billion, noting that the stock is trading near its 52-week high.

FDA advisory panel recommends a first: multi-cancer blood test

https://www.npr.org/2026/09/23/nx-s1-5978122/fda-blood-cancer-test-galleri
An FDA advisory panel has recommended approval for Grail's Galleri blood test, the first multi-cancer detection blood test, for individuals aged 50 and over. While the test can detect up to 50 forms of cancer, concerns were raised about its effectiveness in early detection and potential for false senses of security. The panel's recommendation includes caveats for marketing materials, emphasizing that the test should supplement, not replace, standard cancer screenings.
Advertisement

James Hardie Industries plc(NYSE: JHX) added to S&P TMI Index

https://www.marketscreener.com/news/james-hardie-industries-plc-nyse-jhx-added-to-s-p-tmi-index-ce785ad8db80ff24
James Hardie Industries plc (NYSE: JHX) has been added to the S&P TMI Index, as announced on September 20, 2026. This news comes alongside other recent updates for the company, including its reaffirmation of fiscal 2027 guidance and a recent initiation with a Buy rating by Loop Capital. James Hardie is a provider of exterior home and outdoor living solutions, offering fiber cement siding, fiber gypsum interior walls, and composite decking products across various global markets.

James Hardie Sees $23 Billion North American Material-Conversion Opportunity, RBC Says

https://www.marketscreener.com/news/james-hardie-sees-23-billion-north-american-material-conversion-opportunity-rbc-says-ce785bd2df8ff420
RBC analysts indicate that James Hardie Industries has a significant $23 billion material-conversion opportunity in North America. This article, published on MarketScreener, is reserved for members. James Hardie is a global provider of exterior home and outdoor living solutions, specializing in fiber cement siding and trim, fiber gypsum products, and composite decking.

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

https://finance.yahoo.com/healthcare/articles/vnrx-volitionrx-prepays-outstanding-balance-161700677.html
VolitionRx (VNRX) has prepaid the outstanding balance on a $7.5 million convertible promissory note, significantly reducing potential dilution. The company continues to advance its epigenetics platform, announcing several new clinical validations, partnerships, and scientific publications in mid-2026, particularly for sepsis detection and cancer diagnostics. Financial results for Q2 2026 showed a decrease in operating expenses due to headcount reductions, despite a slight decline in total revenue.

VNRX: VolitionRx Prepays Outstanding Balance on the $7,500,000 Lind Senior Secured Convertible Promissory Note Dated May 20, 2025. Review of Papers, Posters, and Videos Released in Mid-2026. Sysmex Collaboration is the 3rd Recent Agreement in the Human Space.

https://finance.yahoo.com/healthcare/articles/vnrx-volitionrx-prepays-outstanding-balance-161700882.html
VolitionRx (VNRX) has prepaid the outstanding balance on a $7.5 million convertible promissory note and continues to advance its epigenetics platform. The company reported decreased operating expenses and a new collaboration agreement with Sysmex, alongside significant progress in point-of-care sepsis tests and early cancer detection technologies. VolitionRx is also pursuing a reimbursement pathway in France for its Nu.Q Lung Cancer test and expects additional human licensing agreements in 2026.

Apollo Global in talks to acquire J&J’s orthopedics unit, Bloomberg News reports

https://whbl.com/2026/09/11/apollo-global-in-talks-to-acquire-jjs-orthopedics-unit-bloomberg-news-reports/
Apollo Global Management is reportedly in discussions to acquire Johnson & Johnson’s orthopedics unit, DePuy Synthes, in a deal potentially worth $20 billion. J&J has been exploring options for the unit, which generated $9.3 billion in 2025 but faces lawsuits, including a potential spin-off into a publicly traded company. This move aligns with J&J's strategy to focus on higher-growth healthcare segments and follows increased private equity interest in the healthcare sector.
Advertisement

VolitionRX Earnings Call: Scientific Momentum Meets Cash Risks

https://www.tipranks.com/news/company-announcements/volitionrx-earnings-call-scientific-momentum-meets-cash-risks
VolitionRX's Q2 earnings call highlighted significant scientific advancements, including strong validation data for their Nu.Q NETs assay for sepsis and progress in lung cancer detection and feline lymphoma tests. Despite these scientific successes and strategic collaborations, the company faces financial challenges, including flat quarterly revenue, ongoing cash constraints, and execution risks related to regulatory approvals and licensing deals. Investors are left to weigh the compelling innovation story against the company's funding needs and commercialization hurdles.

Carlyle Credit Income Fund (NASDAQ: CCID) logs 10.44% GAAP yield on CLO portfolio

https://www.stocktitan.net/sec-filings/CCID/8-k-carlyle-credit-income-fund-reports-material-event-7dc581cf82c7.html
Carlyle Credit Income Fund (CCIF/CCID) reported its third-quarter 2026 results, showing net investment income of $0.07 per common share and a total weighted average GAAP yield of 10.44% on its CLO portfolio. The fund declared monthly common dividends of $0.06 per share for September, October, and November 2026, representing an annualized rate of 24.91%. CCIF's portfolio consists of 42 CLO holdings with exposure to 1,450 underlying obligors, and its net asset value per common share was $3.32 as of June 30, 2026.

AVITA Medical Number of Employees 2026 | Employee Count & Headcount Data

https://www.reveliolabs.com/companies/avita-medical/employees
AVITA Medical, Inc. (RCEL) had approximately 227 employees worldwide as of June 2026, representing a 1.8% growth since 2023 but a 5.0% decline year-over-year. The company, headquartered in Santa Clarita, California, is actively hiring, with 3 job postings in 2026. Its workforce is primarily concentrated in North America, with an average salary of $147,133.

Earnings call transcript: VolitionRX misses Q2 2026 estimates as shares slip

https://www.investing.com/news/transcripts/earnings-call-transcript-volitionrx-misses-q2-2026-estimates-as-shares-slip-93CH-4860965
VolitionRX (VNRX) reported a wider-than-expected loss and lower revenue for Q2 2026, causing shares to slip. Despite the financial miss, the company highlighted progress in reducing operating costs, advancing scientific data, and developing partnerships in sepsis, cancer, and veterinary diagnostics. Management indicated that revenue remains unpredictable and declined to provide full-year 2026 guidance, focusing instead on long-term strategic milestones and licensing agreements.

LivaNova (LIVN) Q2 2026 Earnings Call Transcript

https://www.theglobeandmail.com/investing/markets/stocks/LIVN/pressreleases/3808224/livanova-livn-q2-2026-earnings-call-transcript/
LivaNova reported record Q2 2026 revenue of $390.6 million and adjusted diluted EPS of $1.26, exceeding prior-year figures, driven by strong demand in Cardiopulmonary and Epilepsy segments. The company raised its full-year 2026 revenue guidance to 8%-9% growth and adjusted diluted EPS guidance to $4.30-$4.40, citing improved market share, Essenz upgrade cycles, and favorable Medicare reimbursement. LivaNova also announced a long-term supply agreement with Thermo Fisher Scientific for oxygenator components and provided updates on its innovation pipeline, including next-generation oxygenators and advancements in its Obstructive Sleep Apnea program.
Advertisement

QIAGEN N.V. (NYSE: QGEN) sets $0.35 dividend and $200M buyback cap

https://www.stocktitan.net/sec-filings/QGEN/6-k-qiagen-n-v-current-report-foreign-issuer-ea6e68964304.html
QIAGEN N.V. (NYSE: QGEN) announced it will convene its 2026 Annual General Meeting on June 24, 2026. Shareholders will vote on a proposed cash dividend of $0.35 per ordinary share, totaling approximately $72 million, payable July 14, 2026. Additionally, the agenda includes authorizing a synthetic share repurchase of up to $200 million via capital repayment, alongside other corporate governance and remuneration policy updates.

QT Imaging appoints two regional sales vice presidents By Investing.com

https://ng.investing.com/news/stock-market-news/qt-imaging-appoints-two-regional-sales-vice-presidents-93CH-2636524
QT Imaging Holdings Inc. (NASDAQ:QTI) has appointed Jason Dyer as Vice President Regional Sales East and Dave Reinhart as Vice President Regional Sales West, effective July 2026. These appointments mark a strategic shift from a distributor-led sales model to a direct sales approach for its Breast Acoustic CT Scanner, though it will continue working with NXC Imaging, Inc. The new team aims to strengthen customer engagement and support clinical adoption, with potential expansion of commercial resources in 2027 and a focus on developing quantitative imaging biomarkers and Software-as-a-Service offerings.

Citigroup readies US$2 bil debt deal for KKR’s Integer buyout — Bloomberg

https://theedgemalaysia.com/node/813377
Citigroup is leading a US$2.45 billion debt financing package for KKR & Co Inc.'s acquisition of medical-device maker Integer Holdings. The financing includes a US$2.1 billion term loan and a US$350 million revolving credit facility, with Barclays Plc, UBS Group AG, and Jefferies Financial Group Inc. also participating. This marks Citigroup's second lead role in a significant medical-device buyout this year, following an US$8.75 billion debt financing for Hologic Inc.

Contrast-Enhanced Mammography (CEM) Explained

https://www.hologic.com/about/newsroom/contrast-enhanced-mammography-explained-conversation-hologic-scientist-wei-wang
This article explains Contrast-Enhanced Mammography (CEM), an imaging option that helps detect breast cancer, especially in women with dense breasts. Dr. Wei Wang, Associate Director of R&D Innovation at Hologic, discusses how CEM uses an iodine-based contrast agent to highlight abnormal blood vessel growth associated with tumors, offering an alternative to MRI. The technology provides crucial functional information for radiologists and is evolving to extract more meaningful data for improved patient decision-making.

Revvity raises annual profit, revenue forecasts on strong diagnostics demand

https://wixx.com/2026/08/04/revvity-raises-annual-profit-revenue-forecasts-on-strong-diagnostics-demand/
Medical equipment maker Revvity has increased its annual profit and revenue forecasts after exceeding Wall Street expectations for the second quarter. This improvement is attributed to stronger demand for its drug-development tools and diagnostic testing products, with AI-related work contributing to incremental demand. Despite a decline in its life sciences unit, the company's diagnostics business saw significant growth.
Advertisement

KKR to take medical equipment maker Integer Holdings private in $5.7 billion deal

https://www.cnbc.com/2026/08/03/kkr-to-take-medical-equipment-maker-integer-holdings-private-in-5point7-billion-deal-.html
Private equity firm KKR is acquiring medical equipment manufacturer Integer Holdings in an all-cash deal valued at approximately $5.7 billion, including debt assumption. KKR will pay $127 per share, a 4.78% premium over Integer's Friday closing price. This acquisition deepens KKR's healthcare exposure and follows Integer's recent agreement with activist investor Irenic Capital Management.

Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics

https://www.streetinsider.com/PRNewswire/Bacterial+Vaginosis+Linked+to+Increased+STI+Co-Infection%2C+Finds+National+Study+of+1.5+Million+Women+from+Quest+Diagnostics/26838837.html
A national Health Trends® study by Quest Diagnostics and Hologic, Inc. found that women testing positive for bacterial vaginosis (BV) were over three times more likely to also have non-viral sexually transmitted infections (STIs). The study, which analyzed data from 1.5 million women between 2022 and 2024, revealed that 12% of BV-positive women were co-infected with at least one STI, compared to 3.8% of BV-negative women. These findings emphasize the need for comprehensive diagnostic approaches and continued research into the link between vaginal microbiome changes and STI susceptibility.

Teleflex Number of Employees 2026 | Employee Count & Headcount Data

https://www.reveliolabs.com/companies/teleflex/employees
Teleflex, Inc. (TFX) had approximately 15,496 employees worldwide as of March 2026, marking a 3.2% growth from 2023. The company, headquartered in Wayne, Pennsylvania, is actively hiring with 295 job postings in 2026, though hiring velocity has declined. Its workforce is primarily concentrated in the United States, and the average employee salary is $75,478.

Ceribell Expands Board of Directors with Appointments of Thomas West and Sharon O’Keefe

https://markets.businessinsider.com/news/stocks/ceribell-expands-board-of-directors-with-appointments-of-thomas-west-and-sharon-o-keefe-1036377616
Ceribell, a medical technology company, announced the appointments of Thomas West and Sharon O’Keefe to its Board of Directors. West brings experience scaling medical technologies and led companies through significant acquisitions, while O’Keefe offers extensive leadership experience from major academic health systems. Their combined expertise is expected to be invaluable as Ceribell expands its point-of-care brain monitoring platform, currently deployed in over 680 U.S. hospitals.

Smith & Nephew Number of Employees 2026 | Employee Count & Headcount Data

https://www.reveliolabs.com/companies/smith-nephew/employees
As of March 2026, Smith & Nephew plc has approximately 18,547 employees worldwide, marking a 1.3% decline since 2023 but a recovery from a low in 2025 Q1. The company is actively hiring with 1,218 active job postings in 2026, a 44.1% increase from 2025. The workforce is concentrated in the United States, Costa Rica, and the United Kingdom, with India being the fastest-growing location, and the average global salary is $71,719.
Advertisement

Hologic Inc Lobbyists, 2022

https://www.opensecrets.org/federal-lobbying/clients/hologic-inc/lobbyists?client_id=179129&cycle=2022
This OpenSecrets.org page details the lobbyists working for Hologic Inc in 2022. It lists 19 lobbyists, 15 of whom have revolving door experience from federal government positions. The data breaks down lobbyists by hiring firm and provides a comprehensive roster for the year.

Hologic stock trades steadily as breast health and diagnostics revenue support valuation

https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-trades-steadily-as-breast-health-and-diagnostics-revenue/69883165
Hologic's stock is maintaining a steady valuation, supported by consistent revenue from its breast health systems and molecular diagnostics segments. Despite the normalization of COVID-19 testing sales from their peak, the company reported significant revenue growth in fiscal 2022, primarily driven by diagnostics and surgical products, and maintained strong operating margins. The article highlights that recurring revenue from breast health and non-COVID molecular diagnostics is crucial for sustaining its profitability above pre-pandemic levels.

Hologic stock steadies as breast health and diagnostics revenue drive outlook

https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-steadies-as-breast-health-and-diagnostics-revenue-drive/69860143
Hologic's stock reflects a mixed picture, balancing stable breast health and diagnostics revenue against cautious guidance. The company, focused on women's health, reported approximately $1.0 billion in quarterly revenue, driven by these core segments despite a normalization in COVID-related testing. Its strong cash flow, manageable debt, and capital allocation strategy, including share repurchases, support its position as a stable, moderately growing medical technology group.

From Hologic to Ark Surgical: Why Joseph LaBruzzo is betting on the future of women’s surgical innovation

https://www.femtechworld.co.uk/news/from-hologic-to-ark-surgical-why-joseph-labruzzo-is-betting-on-the-future-of-womens-surgical-innovation-ark26/
Joseph B. LaBruzzo, previously with leading medical device companies like Hologic, has joined Ark Surgical as President & CEO of U.S. Operations and Board Member. He is drawn to Ark Surgical's LapBox, an innovation addressing unmet needs in gynecologic surgery by enhancing safety during minimally invasive procedures. LaBruzzo believes this technology has the potential to become a standard of care, reflecting his commitment to improving patient outcomes in women's health.

3D Mammography Machines Market To Reach New Heights by 2035 Amid AI Adoption and Global Screening Programs - News and Statistics

https://www.indexbox.io/blog/3d-mammography-machines-market-forecast-points-higher-toward-2035-driven-by-ai-integration-and-screening-expansion/
The global 3D mammography machines market is expected to experience sustained growth, projected at an 8.5% compound annual growth rate from 2026 to 2035, driven by AI integration and expanding screening programs. Key market drivers include the superiority of Digital Breast Tomosynthesis (DBT) over 2D mammography, rising breast cancer incidence, and increased adoption in emerging markets. Despite challenges like high system costs and supply chain constraints, widespread replacement of older 2D systems and significant growth in Asia-Pacific are anticipated.
Advertisement

Hologic stock trades steadily as imaging and diagnostics revenue supports margins

https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-trades-steadily-as-imaging-and-diagnostics-revenue-supports/69837789
Hologic stock maintains steady trading as its diagnostics and surgical portfolio, focused on women's health technology, demonstrates consistent revenue growth and stable margins. The company benefits from a diversified product mix, including high-margin diagnostic consumables and imaging systems, with international expansion further supporting its financial performance. Investors are watching segment trends and market positioning, backed by a strong operating income and strategic investments in R&D.

RadNet schedules Q2 2026 financial results conference call

https://scanx.trade/stock-market-news/companies/radnet-schedules-q2-2026-financial-results-conference-call/46262381
RadNet, Inc. has announced its second quarter 2026 financial results conference call will take place on Monday, August 10, 2026, at 7:30 a.m. Pacific Time. Investors can access the live call via domestic and international dial-in numbers, and an archived replay will also be available. RadNet is a major provider of diagnostic imaging services and AI solutions, operating numerous outpatient imaging centers and developing AI tools under its DeepHealth brand.

Hologic stock trades steadily as diagnostics and surgical revenue support margins

https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-trades-steadily-as-diagnostics-and-surgical-revenue-support/69829048
Hologic's stock is performing steadily, supported by strong revenue growth and resilient margins in its diagnostics and surgical segments. The company's recent quarterly results show a shift from pandemic-driven testing sales to a more balanced portfolio, with core molecular diagnostics and cytology products underpinning recurring revenue. Despite some cost pressures, Hologic maintains profitability levels above pre-pandemic benchmarks, with continued investment in R&D and diversification through breast health and surgical offerings.

Hologic stock trades steadily as recent earnings highlight diagnostics growth

https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-trades-steadily-as-recent-earnings-highlight-diagnostics/69824619
Hologic Inc. (HOLX) stock has been trading steadily, supported by strong fundamentals thanks to its diagnostics and surgical franchises. The company reported higher revenue and improved profitability in Q2 fiscal 2025, driven by its diagnostics segment and solid demand in breast and skeletal health. Hologic has also provided stable full-year guidance and maintains strong cash flow generation.

Hologic stock trades steadily as Q2 2025 earnings show higher margins

https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-trades-steadily-as-q2-2025-earnings-show-higher-margins/69802758
Hologic's Q2 2025 earnings reveal a solid financial profile driven by growing margins and consistent cash generation, particularly in women’s health diagnostics. The company's revenue stability across key segments like diagnostics, breast and skeletal health, and gynecologic surgical products, coupled with a robust balance sheet, positions it well for continued innovation and sustained profitability in the medical technology sector. This performance underpins Hologic's stability, making it an attractive prospect for investors interested in the sustainability of diagnostic volumes and effective capital allocation.
Advertisement

Hologic (HOLX) Q4 2024 earnings summary

https://quartr.com/events/hologic-holx-q4-2024_3YWDV2ZB
Hologic (HOLX) reported strong Q4 2024 results, with revenue reaching $987.9 million, up 4.5% year-over-year, and non-GAAP EPS of $1.01. The company saw broad-based growth across Diagnostics, Breast Health, and Surgical segments, driven by strategic acquisitions and international expansion. Hologic also announced a $250 million accelerated share repurchase program and provided optimistic financial guidance for FY2025, projecting revenue between $4.15 billion and $4.20 billion.

Hologic stock trades steadily as breast health revenue supports outlook

https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-trades-steadily-as-breast-health-revenue-supports-outlook/69792160
Hologic stock is trading steadily on Nasdaq, supported by strong quarterly results for Q2 fiscal 2025 which showed increased revenue in both its Diagnostics and Breast Health segments. The company reported double-digit growth in Diagnostics and mid-single-digit growth in Breast Health, contributing to an improved operating margin. Hologic's capital allocation strategy includes continued investment in R&D and significant share repurchases, with a net leverage ratio indicating financial flexibility.

Hologic stock trades steadily as diagnostics growth offsets softer imaging demand

https://www.ad-hoc-news.de/boerse/news/ueberblick/hologic-stock-trades-steadily-as-diagnostics-growth-offsets-softer-imaging/69784863
Hologic's stock performance is analyzed, showing stable diagnostics revenue balancing softer demand in its imaging and surgical segments. The company reported a 5% increase in net revenue for Q2 fiscal 2024, driven by its diagnostics business, and maintained robust adjusted operating margins and EPS. Hologic's focus on women's health and recurring diagnostics revenue provides a strong foundation, while its diversified segments offer cyclical growth opportunities.

Full Transcript: AngioDynamics Q4 2026 Earnings Call

https://www.sahmcapital.com/news/content/full-transcript-angiodynamics-q4-2026-earnings-call-2026-07-14
AngioDynamics reported strong Q4 fiscal year 2026 results with an 8% revenue increase to $86.6 million, driven by 16.7% growth in its MedTech segment, which now accounts for 47% of total revenue. The company highlighted 20 consecutive quarters of double-digit growth for its Aureon platform and a 64.5% revenue increase for NanoKnife, particularly in prostate care. For fiscal 2027, AngioDynamics projects 5-6.5% total revenue growth and 12-15% MedTech sales growth, emphasizing continued investment in clinical data, R&D, and a debt-free balance sheet.

CE-IVDR Mark for Hologic’s Aptima® HPV Test Expanded to Include Self-Collected Sample Claim in Cervical Cancer Screening

https://www.biospace.com/press-releases/ce-ivdr-mark-for-hologics-aptima-hpv-test-expanded-to-include-self-collected-sample-claim-in-cervical-cancer-screening
Hologic, Inc. announced an expanded CE-IVDR marking for its Aptima® HPV Assay in the European Union and the UK, now approved for self-collected vaginal samples. This expansion aims to improve cervical cancer screening participation rates, especially for women facing barriers to traditional screening methods. While self-sampling increases access, positive results still necessitate clinician-collected cervical samples for appropriate follow-up care and management.
Advertisement
Advertisement
Advertisement
Advertisement

Sign Up free to view live trades and discussion forum to make more informed financial decisions. No credit card is required for sign up!
View Daily Trades
Join Discussion

Advertisement
Advertisement
Advertisement
Advertisement